Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy.

PubWeight™: 0.92‹?›

🔗 View Article (PMC 3853426)

Published in Am J Transl Res on December 01, 2013

Authors

Hong Yu1, Bensong Duan2, Lin Jiang3, Mei Lin4, Haihui Sheng5, Junxing Huang4, Hengjun Gao6

Author Affiliations

1: Department of Pathology, Taizhou People's Hospital Taizhou, Jiangsu, China.
2: Institute of Digestive Disease, Department of Gastroenterology, Tongji Hospital, Tongji University Shanghai, China.
3: Department of Anesthesiology, Taizhou People's Hospital Taizhou, Jiangsu, China.
4: Department of Oncology, Taizhou People's Hospital Taizhou, Jiangsu, China.
5: CMC Biobank and Translational Medicine Institute Taizhou, Jiangsu, China ; National Engineering Center for Biochip at Shanghai Shanghai, China ; Shanghai Engineering Center for Molecular Medicine Shanghai, China.
6: Institute of Digestive Disease, Department of Gastroenterology, Tongji Hospital, Tongji University Shanghai, China ; Shanghai Engineering Center for Molecular Medicine Shanghai, China.

Articles cited by this

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27

Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17

Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65

Reporting results of cancer treatment. Cancer (1981) 28.83

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27

Esophageal cancer. N Engl J Med (2003) 15.23

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem (2008) 10.08

PI3K/Akt signalling pathway and cancer. Cancer Treat Rev (2004) 5.46

Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24

MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene (2008) 4.11

MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther (2009) 2.50

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol (2013) 2.09

Genetic polymorphisms and esophageal cancer risk. Int J Cancer (2007) 2.02

Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression. Cell Cycle (2009) 1.97

Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol (2009) 1.84

Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res (2011) 1.59

Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg (2009) 1.48

Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg (2014) 1.46

The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond) (2011) 1.34

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med (2012) 1.31

MiR-200c and HuR in ovarian cancer. BMC Cancer (2013) 1.18

18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med (2012) 1.18

MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res (2013) 1.14

A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer (2013) 1.10

Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol (2013) 1.10

Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol (2013) 1.08

Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer (2013) 1.05

Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. J Toxicol Environ Health A (2012) 1.03

MiR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway. PLoS One (2013) 1.00

Prognostic significance of serum miR-17-5p in lung cancer. Med Oncol (2012) 0.99

miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol (2011) 0.88

Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene (2014) 0.86